Oculus Innovative Sciences
This article was originally published in The Gray Sheet
Executive Summary
Petaluma, Calif., company will launch the first hydrogen version of its Microcyn technology July 1. Microcyn Skin and Wound Hydrogel received FDA clearance in May for management of exuding wounds such as leg ulcers and diabetic ulcers, and for management of mechanically or surgically debrided wounds. In early June, Oculus announced its original Microcyn Skin and Wound Cleaner received 510(k) clearance for debridement of wounds such as stage I-IV pressure ulcers, partial and full thickness wounds, diabetic foot ulcers, post-surgical wounds, and first- and second-degree burns. During the company's June 11 fourth-quarter earnings call, Oculus CEO Hoji Alimi said studies have shown Microcyn technology to be effective in wound healing, but the company says it is not marketing the product for that claim. Oculus declined to say whether the company would seek a wound healing indication for Microcyn in the future